PISCES III — A randomized, placebo-controlled study of the efficacy and safety of intracerebral stem cells (CTXOE03) in subjects with disability following an ischemic stroke.

HS 2018-4779
Stroke, Brain & Nerve, Brain Injury - Traumatic
Leonid Groysman, MD

UCI Medical Center, UCI campus

The purpose of this study is to determine whether a new stem cell therapy drug called CTXOE03 can improve motor functions in people with ongoing disability after an ischemic stroke when injected into the affected area of the brain.

Please note this may not be a complete list of eligibility criteria. We have included a few examples of study criteria to help you better understand how your eligibility in the study will be determined; your study team will go through the study eligibility criteria with you to verify if you qualify for participation in this study.

Inclusion requirements:

  • Had an ischemic stroke in the last 6-12 months and still have some disability
  • Are between the ages of 35 and 75
  • Have some movement left in your affected limb
  • Are able to understand and sign an informed consent form

Exclusion requirements:

  • Had permanent disability prior to the ischemic stroke
  • Had a hemorrhagic stroke
  • Have a history of any significant neurological condition or disorder (Parkinson's disease, dementia, etc).
  • Had cancer diagnosis within the last 5 years
  • Had a brain tumor

Study participation lasts 12 months, from the surgical procedure until the last follow-up visit. There is a screening phase of up to six weeks prior to surgery.

No subject can be guaranteed individual benefits from participation. Previous studies suggest that ischemic stroke patients could benefit from the investigational study drug.

Participants will be paid $50 at specified time points over the course of the study. These payments are meant to cover the time required to complete these study visits and all necessary travel and parking expenses.

CTXOE03
Stem cell therapy
UCI Alpha Stem Cell Clinic
949-824-3990